Analytical Reports on Amgen Inc. and Biogen Idec Inc. - Biotech Companies Look to Promising Future

NEW YORK, NY -- (Marketwire) -- 08/11/11 -- www.SignalWatcher.com provides members with proprietary analysis of over 10,000 stocks which is updated every day. Today, members can receive their complimentary stock analysis on Amgen Inc. (NASDAQ: AMGN) and Biogen Idec Inc. (NASDAQ: BIIB). Sign up now on www.SignalWatcher.com to get your free reports on these stocks.

While the financial news has not been positive for all companies in the Biotechnology Sector, the industry as a whole has performed well over the last year and could continue to do so well into the future. The population of many developed countries is quickly aging, and the current and future health problems of senior citizens could benefit Biotech companies greatly.

www.SignalWatcher.com brings investors free classic analysis on Amgen Inc., Biogen Idec Inc. and other companies within the Biotechnology industry. This type of analysis is only a fragment of the information members have available to them. To learn more we encourage investors to sign up at http://signalwatcher.com/EmailSignup.php.

Companies in the industry like Amgen Inc. and Biogen Idec Inc. continually attempt to test and get approval in major markets like the United States and the European Union for new biotech drugs. One example is the stiff competition currently going on between new and established biotech drugs that are meant to treat and ease the effects of Multiple Sclerosis. www.SignalWatcher.com gives traders a unique insight about Amgen Inc. and Biogen Idec Inc. by registering now at

http://signalwatcher.com/AMGN/August112011.php or

http://signalwatcher.com/BIIB/August112011.php.

One issue currently at hand is the development and testing of "biosimilar" drugs. These drugs are the sector's generics and in many cases are being seen as more difficult to test and approve for use in the public because of their complicated nature. Unlike chemical-based drugs, biotech drugs cannot be copied perfectly, making the approval process more difficult and complicated for regulators. These factors could make testing more time consuming and expensive for generic biotech companies, negatively affecting their bottom-line.

About Signal Watch

Signal Watch's #1 goal is to help customers successfully engage the markets. For over 20 years, we have been developing the most powerful trading software available anywhere. But the software is only part of our mission. We also provide education and customer support designed to enable our customers to take control of their financial future.

Read our disclaimer by clicking on the following link http://www.signalwatch.com/disclaimers.aspx

For More Information Contact:

Eric Avalos
Marketing Advisor


info@signalwatcher.com

Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here